In autosomal dominant polycystic kidney disease, the use of anti-AREG antibodies and inhibitors of activator protein-1 (AP1) can reduce cell proliferation in cystic cells by reducing AREG expression and EGFR activity [154]. This evidence concerns the gene AREG and autosomal dominant polycystic kidney disease.